GRAIL Inc (GRAL) AI Stock Analysis

• Market Cap: $2.86B
• Dividend Yield: N/A
• Average Volume (3M): 1.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.80
• Revenue Growth: 20.53%
• EPS Growth: 82.91%
• Country: US
• Employees: 1,000
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -2.46
• Shares Outstanding: 36,047,800
• 10 Day Avg. Volume: 1,009,555
• 30 Day Avg. Volume: 1,199,319
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.23
• Price to Sales (P/S): 4.53
• P/FCF Ratio: -0.98
• Enterprise Value/Market Cap: 0.45
• Enterprise Value/Revenue: 9.17
• Enterprise Value/Gross Profit: -19.28
• Enterprise Value/Ebitda: -3.39
• 1Y Price Target: $60.86
• Price Target Upside: -27.30% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: $123.00 ▲(46.94% Upside)

GRAIL Inc. benefits from strong technical momentum and strategic growth initiatives, which are the most significant factors driving the score. However, financial performance challenges and valuation concerns due to ongoing losses and a negative P/E ratio temper the overall outlook.

Positive Factors

Revenue Growth

GRAIL's strong revenue growth indicates increasing demand for its cancer detection tests, enhancing its market position and potential for future profitability.

Strategic Partnerships

The partnership with Samsung expands GRAIL's market reach in Asia, potentially increasing revenue streams and solidifying its international presence.

Financial Stability

The private placement enhances GRAIL's liquidity, providing a cash runway into 2030, which supports long-term operational stability and strategic initiatives.

Negative Factors

Profitability Challenges

Ongoing losses and negative margins highlight profitability challenges, which could hinder GRAIL's ability to sustain operations without external financing.

Regulatory Delays

Potential delays in FDA approval could impact GRAIL's ability to fully commercialize its products, affecting revenue and market expansion plans.

Cash Flow Challenges

Low operating cash flow relative to net income suggests reliance on external funding, which could limit financial flexibility and growth initiatives.

GRAIL Inc Business Overview & Revenue Model

Company Description

GRAIL Inc. is a biotechnology company focused on the early detection of cancer through its innovative multi-cancer early detection (MCED) blood tests. The company operates primarily in the healthcare sector, leveraging advanced genomic technologies and data analytics to develop its core products. GRAIL aims to transform cancer screening by providing tests that can detect multiple types of cancer at their earliest stages, thereby improving patient outcomes and enabling timely intervention.

How the Company Makes Money

GRAIL generates revenue primarily through the sale of its multi-cancer early detection tests to healthcare providers, hospitals, and laboratories. The company operates a direct-to-consumer model as well, allowing individuals to access its testing services. Key revenue streams include the fees charged for each test performed, as well as potential partnerships with healthcare organizations and insurers that may facilitate broader access to its products. GRAIL also benefits from collaborations with pharmaceutical companies and research institutions, which may involve funding for clinical studies or development efforts aimed at integrating its testing solutions into broader cancer care protocols.

GRAIL Inc Financial Statement Overview

Summary

GRAIL Inc. shows strong revenue growth but faces significant profitability challenges with negative margins. The company maintains financial stability through a strong equity position and low leverage, but cash flow remains a concern due to negative free cash flow and reliance on external financing.

Income Statement

GRAIL Inc. has shown substantial revenue growth with a 34.89% increase from 2023 to 2024. However, the company continues to operate at a loss with a negative gross profit margin of -62.12% and a net profit margin of -161.42% in 2024. The EBIT and EBITDA margins are also negative, indicating ongoing operational challenges.

Balance Sheet

GRAIL Inc. maintains a strong equity position with an equity ratio of 83.92%. The debt-to-equity ratio is low at 0.03, signifying limited leverage. However, the return on equity is negative due to ongoing losses. The company's high stockholders' equity relative to total assets suggests financial stability but profitability remains a concern.

Cash Flow

The operating cash flow to net income ratio is 0.28, indicating cash flow challenges. Free cash flow has improved slightly, but remains negative at -$582.36 million. The company raised $1.24 billion in financing activities, aiding liquidity but highlighting reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	141.83M	125.59M	93.11M	55.55M	14.61M	0.00
Gross Profit	-67.41M	-78.02M	-95.61M	-116.45M	-100.00M	0.00
EBITDA	-383.24M	-610.17M	-638.22M	-587.70M	-1.21B	-308.73M
Net Income	-406.24M	-2.03B	-1.47B	-5.40B	-1.25B	-312.16M
Balance Sheet
Total Assets	2.60B	2.98B	4.56B	5.60B	9.74B	706.30M
Cash, Cash Equivalents and Short-Term Investments	540.13M	763.47M	97.29M	241.60M	221.16M	583.48M
Total Debt	58.59M	68.14M	84.41M	96.01M	110.56M	62.99M
Total Liabilities	361.07M	479.90M	910.74M	955.94M	307.40M	144.46M
Stockholders Equity	2.24B	2.50B	3.65B	4.65B	9.43B	561.84M
Cash Flow
Free Cash Flow	-329.83M	-582.36M	-608.69M	-584.17M	-758.06M	-243.91M
Operating Cash Flow	-328.71M	-577.16M	-595.80M	-561.31M	-688.13M	-232.00M
Investing Cash Flow	-394.45M	-551.01M	-12.89M	-22.86M	344.81M	-12.79M
Financing Cash Flow	0.00	1.24B	463.77M	604.82M	394.74M	275.11M

GRAIL Inc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 83.71
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRAL, the sentiment is Positive. The current price of 83.71 is below the 20-day moving average (MA) of 89.79, above the 50-day MA of 77.46, and above the 200-day MA of 46.61, indicating a bullish trend. The MACD of 8.23 indicates Negative momentum. The RSI at 68.57 is Neutral, neither overbought nor oversold. The STOCH value of 84.42 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GRAL.

GRAIL Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ILMN	73 Outperform	$20.09B	29.45	31.20%	―	-2.39%	―
GRAL	70 Outperform	$2.86B	―	-16.83%	―	20.53%	82.91%
NTRA	68 Neutral	$32.96B	―	-29.02%	―	38.17%	-28.77%
GH	58 Neutral	$14.03B	―	―	―	30.38%	24.17%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
NEO	55 Neutral	$1.57B	―	-12.99%	―	10.10%	-44.29%
MYGN	49 Neutral	$711.22M	―	-72.52%	―	0.21%	-233.51%

GRAIL Inc Corporate Events

Grail Inc. Reports Strong Q3 Growth and Strategic Advances

Grail Inc. is a healthcare company focused on early cancer detection using advanced sequencing and machine learning technologies, aiming to alleviate the global cancer burden. In its third-quarter 2025 earnings report, Grail Inc. announced a significant increase in revenue and test sales, with U.S. Galleri revenue growing by 28% year-over-year to $32.6 million and Galleri test sales increasing by 39% to over 45,000 tests. The company also highlighted its strong cash position of over $850 million, bolstered by a recent private placement.

GRAIL Inc Secures $325 Million in Private Placement

On October 18, 2025, GRAIL, Inc. entered into a Securities Purchase Agreement for a private placement, expected to raise approximately $325 million. The proceeds will support GRAIL’s commercial activities, reimbursement efforts, and general corporate purposes, with the closing expected on October 21, 2025. This financing round includes participation from new and existing institutional investors and is anticipated to fund operations into 2030, excluding a separate $110 million investment from Samsung. The private placement is exempt from registration under the Securities Act, with GRAIL agreeing to file a registration statement for the resale of shares.

The most recent analyst rating on (GRAL) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on GRAIL Inc stock, see the GRAL Stock Forecast page.

GRAIL Inc Partners with Samsung for $110M Investment

On October 16, 2025, GRAIL, Inc. entered into a stock purchase agreement with Samsung C&T Corporation and Samsung Electronics to issue and sell shares worth $110 million in a private placement. This strategic collaboration aims to commercialize GRAIL’s Galleri multi-cancer early detection test in South Korea, with potential expansion to Japan and Singapore. The agreement includes conditions such as regulatory approvals and the execution of business and strategic collaboration agreements by early 2026. This partnership is expected to strengthen GRAIL’s market position in Asia and provide financial support for its commercialization and reimbursement efforts.

The most recent analyst rating on (GRAL) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on GRAIL Inc stock, see the GRAL Stock Forecast page.

GRAIL Inc Signs New Headquarters Lease Agreement

GRAIL, Inc. has entered into a commercial lease agreement for a new corporate headquarters in Sunnyvale, California, covering approximately 75,556 square feet. The lease, starting in October 2026 and ending in September 2037, includes an initial monthly rent of $449,558 with annual increases, and provides options for expansion and renewal.

The most recent analyst rating on (GRAL) stock is a Hold with a $34.00 price target. To see the full list of analyst forecasts on GRAIL Inc stock, see the GRAL Stock Forecast page.

Grail Inc’s Galleri Test Faces Uncertainty Amid Regulatory Challenges and Rising Competition

Grail Inc faces a potential business risk due to the uncertain regulatory environment surrounding Laboratory Developed Tests (LDTs) and the FDA’s authority to regulate them as medical devices. The company has heavily invested in obtaining a Pre-Market Approval (PMA) for its Galleri test, which could enhance its market position and adoption rates. However, if the FDA cannot enforce its authority, competitors may benefit from less stringent regulations, leading to increased competition. This shift could challenge Grail Inc’s ability to adapt, potentially impacting its business and future prospects.

Grail Inc’s Earnings Call Highlights Growth and Optimism

Grail Inc’s recent earnings call conveyed a predominantly positive sentiment, highlighting significant revenue growth, increased sales, and favorable study outcomes. Despite facing some operational hurdles and reporting a net loss, the overall outlook remains optimistic.